WSTWest Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) sells medical packaging, containment systems, and delivery devices for injectable drugs, with a focus on biologics and GLP-1 therapies. The next catalyst is Oct 29, 2026 — Q3 2026 Earnings Release, which will test the durability of its recent revenue growth and the strength of its biologics and GLP-1 component sales.
- Revenue grew 6.3% YoY to $3.29B in 2026, with net income at $571.60M and free cash flow of $629.10M.
- Net margin stands at 17.4%, with a debt-to-equity ratio of 0.06x, suggesting strong leverage and financial flexibility.
- Free cash flow has been a consistent driver, with a 2026 TTM figure of $629.10M, reflecting operational efficiency and pricing power.
The Read
4% after Q2 results beat estimates and raised full-year guidance on robust biologics and GLP-1 component sales.
The schedule
- Thu22Oct
- Tue9Feb
- Tue11May
- Thu22Jul
Past
- Thu23Jul
Actual outcome: Bull · $339.59 at outcome
West Pharmaceutical delivered a strong Q2, beating revenue estimates and reporting adjusted EPS of $2.37, while raising its full-year sales and profit guidance. The stock surged past the bull target as investors cheered the upgraded outlook and robust demand for the company's high-value product components, particularly those used in biologics and GLP-1 injectable drugs.
- Thu5Mar
Actual outcome: Bull · $254.80 at outcome
West Pharmaceutical Services shares rose 4.3% to reach the bull target, driven by positive sentiment surrounding its growth prospects from high-value components and surging GLP-1 drug demand. The stock's appeal as a stable dividend aristocrat amid geopolitical tensions, alongside an orderly transition plan for retiring CEO Eric Green, further bolstered investor confidence and supported the continued rally.
- Tue17Feb
Actual outcome: Mixed · $244.22 at outcome
WST reported EPS actual of 1.83, matching the estimate, with positive FY2026 guidance that signaled improved demand and operational efficiency. The stock rallied as the guidance and strategic developments reinforced long-term growth prospects, driving the price above the bull target.
